Rigel Pharmaceuticals announced that final Phase 3 trial data for GAVRETO (pralsetinib) as a first-line treatment for RET fusion-positive non-small cell lung cancer (NSCLC) will be presented at ASCO 2026, showing improved progression-free survival and response rates over standard care. Additionally, data from Phase 1/2 trials of pralsetinib in RET-altered thyroid cancer and real-world evidence supporting REZLIDHIA (olutasidenib) for relapsed/refractory IDH1-mutated acute myeloid leukemia (AML) were presented. These findings highlight the clinical relevance of Rigel's oncology portfolio and suggest olutasidenib may be an effective post-venetoclax therapy for AML patients. The presentations at ASCO and EHA 2026 will further inform treatment strategies for these difficult-to-treat cancers.
Interim results from the Phase 3 DASL-HiCaP trial show that adding darolutamide to standard androgen deprivation therapy (ADT) and radiation therapy reduces the risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence...
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
Betterware is rated a Buy at around $15 per share, with a medium to long-term price target of approximately $25, supported by potential gains from acquiring Tupperware. Management forecasts revenue growth of 24-26% and an EBITDA margin near 19% for f...
Analyst Benjamin Cowen notes a chart pattern suggesting Bitcoin could reach a local low around mid-November, though no exact date or price is given. The pattern is based on price moves near the 21st of each month but is not yet a confirmed recurring ...
Crypto analyst Dennis Liu estimates that altcoins have about a 40% chance of outperforming Bitcoin during the current market cycle. He also assigns a 50% probability that altcoins will trade sideways relative to Bitcoin, and a 10% chance they will un...
